Navigation Links
bioRASI Completes Acquisition of Ukrainian CRO
Date:3/28/2013

Aventura, FL (PRWEB) March 28, 2013

bioRASI, a full service, global Contract Research Organization (CRO), announced today that it has acquired Sponsors Clinical Research Group, LLC (SCRG), a Ukrainian based regulatory and clinical CRO. SCRG was established in 2004 and has been conducting clinical studies in an extensive range of therapeutic areas including cardiology, neurology, oncology, endocrinology and pulmonology.

“We have been working with SCRG for over a year and have been impressed with the superior expertise of its staff, so it was only natural to consider a more integrated structure,” explained Dr. Boris Reznik, Chairman of bioRASI. “This acquisition enhances bioRASI’s global infrastructure focused on delivering optimized clinical development for our sponsors who are under increasing pressure to accelerate drug development timelines while minimizing costs.”

The acquisition of SCRG addresses the ever-increasing demand for optimizing global clinical trials and builds upon bioRASI’s already commanding presence throughout Eastern Europe.

“While SCRG has been working for many global sponsors and CROs, we have never experienced the powers of project management comparable to that of bioRASI,” explained Dr. Veklych, SCRG’s Executive Director. “An integrated set of tools embodied in the bioRASI Process Infrastructure (BPI) greatly enhances optimized project delivery capabilities. We are excited about being a part of bioRASI’s winning team.”    

About bioRASI
bioRASI is an award-winning Full Service Global CRO providing clinical development services that optimize its sponsors’ scientific, clinical, and business results. bioRASI facilitates obtaining global marketing approval for drugs, biotherapeutics, and medical devices by delivering high quality regulatory and clinical strategies, solutions and services. The Company's unique access to the largest facilities and patient populations worldwide saves clients critical time. bioRASI's services include program optimization, project management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI is headquartered in Aventura, FL and has regional offices and operations across North America and around the world.

Click here for a copy of our White Paper Series.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10578507.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Novira Therapeutics Completes $25 Million Series A Financing
2. BGI-Shenzhen Completes Acquisition of Complete Genomics
3. Amarantus Completes Name Change and CUSIP Change
4. Advanced Cell Diagnostics Completes $12 Million Series B Financing
5. Synthetic Biologics Completes $10.8 Million Private Placement Financing
6. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
7. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
8. Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
9. China Integrated Energy Inc. Completes Independent Investigation
10. Oxford Finance Completes $271.4 Million Securitization Transaction
11. inVentiv Health Completes Acquisition of Kforce Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... 27, 2017 , ... Arrowhead Publishers is pleased to announce ... to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, biotech, ... in the treatment of various types of pain. There are also extended networking ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... the 2017 Borlaug CAST Communication Award goes to Jayson Lusk, a consummate communicator ... forms of media to advocate for science, as he explains how innovation and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ... I clinical trials comes to Tampa, San Francisco and Boston in 2017. ... FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix ...
(Date:4/26/2017)... 26, 2017  Genisphere LLC, provider of the ... a collaborative and sponsored research agreement with the ... . The overall goal of the partnership is ... 3DNA designs and formulations after in vivo ... the vasculature as well as inflammatory responses, demonstrating ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):